Neshanic Station, NJ, United States of America

Francis A Volz



Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 29(Granted Patents)


Location History:

  • Philadelphia, PA (US) (2003)
  • Neshanic Station, NJ (US) (2003 - 2010)

Company Filing History:


Years Active: 2003-2010

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Francis A Volz

Introduction

Francis A Volz is a notable inventor based in Neshanic Station, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on P2X7 ion channel blockers. With a total of 4 patents, his inventions are aimed at addressing various diseases with inflammatory components.

Latest Patents

One of his latest patents involves a novel series of heterocyclic compounds, specifically 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives. These compounds are designed to act as P2X7 ion channel blockers, which are useful as pharmaceutical agents. The invention outlines methods for synthesizing these compounds, which have potential applications in treating inflammatory bowel disease, rheumatoid arthritis, and conditions associated with the central nervous system, such as stroke and Alzheimer's disease.

Career Highlights

Francis A Volz is currently associated with Aventis Pharmaceuticals Inc., where he continues to develop innovative solutions in the pharmaceutical industry. His work has been instrumental in advancing the understanding and treatment of diseases that involve inflammatory processes.

Collaborations

Throughout his career, Volz has collaborated with notable colleagues, including Daniel Gerard McGarry and Patrick Shum. These collaborations have contributed to the successful development of his patented inventions.

Conclusion

Francis A Volz exemplifies the spirit of innovation in the pharmaceutical field, with his work on P2X7 ion channel blockers paving the way for new treatments for various inflammatory diseases. His contributions continue to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…